Journal: Biomedicines

Article Title: The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.

doi: 10.3390/biomedicines12040926

Figure Lengend Snippet: Figure 1. Marker expression in GBM tissues. Representative micrographs showing weak (1 point), medium (2 points) and strong (3 points) cytoplasmic expression of (A) AGTRAP, (B) ALKBH3, (C) DIVERSIN, (D) NEDD8c and (F) RRM1. The H-score was subsequently calculated according to the formula (1 × X) + (2 × Y) + (3 × Z), where X + Y + Z = 100% of the total tumour area. (E) The 5-tier score for nuclear NEDD8 (NEDD8n) according to the percentage of positive cells.

Article Snippet: The AGTRAP, ALKBH3 and DIVERSIN antibodies were purchased from Proteintech Europe (Manchester, UK), while NEDD8 and RRM1 were from Cell Signaling Technology (Frankfurt am Main, Germany).

Techniques: Marker, Expressing

Journal: Biomedicines

Article Title: The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.

doi: 10.3390/biomedicines12040926

Figure Lengend Snippet: Figure 2. Marker expression in healthy versus GBM tissues. Expression of (A) AGTRAP, (C) ALKBH3, (E) DIVERSIN, (G) NEDD8c and (I) RRM1 in GBM (n = 186) and tumour-free ad- jacent brain tissues (n = 54). The medians are shown as black lines and the percentiles (25th and 75th) as vertical boxes with error bars. The outliers are indicated by circles. Statistical analysis was performed with the Mann–Whitney U test, and the p-values are indicated in the upper-right corner of each plot. (B,D,F,H,J) Representative micrographs showing the expression of the markers in the solid tumour area (T) versus the adjacent, tumour-free tissue area (H).

Article Snippet: The AGTRAP, ALKBH3 and DIVERSIN antibodies were purchased from Proteintech Europe (Manchester, UK), while NEDD8 and RRM1 were from Cell Signaling Technology (Frankfurt am Main, Germany).

Techniques: Marker, Expressing, MANN-WHITNEY

Journal: Biomedicines

Article Title: The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis.

doi: 10.3390/biomedicines12040926

Figure Lengend Snippet: Figure 4. New univariate analysis of DIVERSIN and RRM1 in relation to the overall survival of GBM patients. The expression levels of (A) DIVERSIN and (B) RRM1 were dichotomised into ‘low’ and ‘high’ according to the median values of the healthy tissues. Kaplan–Meier curves were generated for the 36-month overall survival, and statistical analysis was performed with the log-rank test. The p-values are indicated in the upper-right corner of each plot.

Article Snippet: The AGTRAP, ALKBH3 and DIVERSIN antibodies were purchased from Proteintech Europe (Manchester, UK), while NEDD8 and RRM1 were from Cell Signaling Technology (Frankfurt am Main, Germany).

Techniques: Expressing, Generated

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Quantifying the mRNA epitranscriptome reveals epitranscriptome signatures and roles in cancer

doi: 10.1007/s00018-025-05805-7

Figure Lengend Snippet: siRNA decreases the mRNA and protein levels of m 1 A regulatory enzymes in HeLa cells. (A) Relative expression changes of mRNA for TRMT10C , ALKBH3 , TRMT6 , TRMT61A , and TRMT6-61 A were measured by RT-qPCR. The x-axis represents the treatment groups, while the y-axis indicates the mRNA expression changes of m 1 A regulatory enzymes relative to the reference gene (GAPDH). (B) Protein level changes of TRMT10C, ALKBH3, TRMT6, TRMT61A, and TRMT6-61 A were assessed by Western blotting. Protein bands were quantified using ImageJ software. The x-axis represents the treatment groups, and the y-axis shows the changes in m1A regulatory enzymes relative to the reference gene (GAPDH). Each group was conducted with three biological replicates. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The protein samples were incubated with the corresponding primary antibodies: TRMT6 Polyclonal Antibody (Proteintech), TRMT10C Polyclonal Antibody (Proteintech), ALKBH3 Polyclonal Antibody (Proteintech), and TRMT61A Polyclonal Antibody (ORIGENE), followed by incubation with the respective secondary antibodies: Multi-rAb HRP-Goat Anti-Mouse Recombinant Secondary Antibody (Proteintech) and Multi-rAb HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (Proteintech).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Software

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Quantifying the mRNA epitranscriptome reveals epitranscriptome signatures and roles in cancer

doi: 10.1007/s00018-025-05805-7

Figure Lengend Snippet: Effects of m 1 A regulatory enzyme knockdown on cell viability. (A) CCK8 assay evaluating changes in cell proliferation following knockdown of m 1 A regulatory enzymes TRMT10C , ALKBH3 , TRMT6 , TRMT61A , and TRMT6-61 A at 6 h, 24 h, 48 h, and 72 h. The x-axis represents treatment duration, and the y-axis indicates cell viability. Each group consists of three biological replicates. * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Flow cytometry measurement of apoptosis rates after 72 h of knockdown of m 1 A regulatory enzymes TRMT10C , ALKBH3 , TRMT6 , TRMT61A , and TRMT6-61 A . Cell apoptosis percentages were quantified using GraphPad Prism software; the x-axis represents m 1 A regulatory enzymes, and the y-axis represents the percentage of apoptosis. Each group consists of three biological replicates. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The protein samples were incubated with the corresponding primary antibodies: TRMT6 Polyclonal Antibody (Proteintech), TRMT10C Polyclonal Antibody (Proteintech), ALKBH3 Polyclonal Antibody (Proteintech), and TRMT61A Polyclonal Antibody (ORIGENE), followed by incubation with the respective secondary antibodies: Multi-rAb HRP-Goat Anti-Mouse Recombinant Secondary Antibody (Proteintech) and Multi-rAb HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (Proteintech).

Techniques: Knockdown, CCK-8 Assay, Flow Cytometry, Software

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Quantifying the mRNA epitranscriptome reveals epitranscriptome signatures and roles in cancer

doi: 10.1007/s00018-025-05805-7

Figure Lengend Snippet: Transcriptomic and proteomic analysis of TRMT6-61 A treated HeLa cells: Transcriptome: (A) Top 20 KEGG enrichment bubble chart. Proteome: (B) Top 25 connectivity protein interaction network diagram. Combined transcriptomic and proteomic analysis: (C) Bar chart of the top 30 KEGG (GSEA) pathways shared across different omics

Article Snippet: The protein samples were incubated with the corresponding primary antibodies: TRMT6 Polyclonal Antibody (Proteintech), TRMT10C Polyclonal Antibody (Proteintech), ALKBH3 Polyclonal Antibody (Proteintech), and TRMT61A Polyclonal Antibody (ORIGENE), followed by incubation with the respective secondary antibodies: Multi-rAb HRP-Goat Anti-Mouse Recombinant Secondary Antibody (Proteintech) and Multi-rAb HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (Proteintech).

Techniques:

Journal: Biomedicines

Article Title: The Roles of AGTRAP, ALKBH3, DIVERSIN, NEDD8 and RRM1 in Glioblastoma Pathophysiology and Prognosis

doi: 10.3390/biomedicines12040926

Figure Lengend Snippet: Marker expression in GBM tissues. Representative micrographs showing weak (1 point), medium (2 points) and strong (3 points) cytoplasmic expression of ( A ) AGTRAP, ( B ) ALKBH3, ( C ) DIVERSIN, ( D ) NEDD8c and ( F ) RRM1. The H-score was subsequently calculated according to the formula (1 × X) + (2 × Y) + (3 × Z), where X + Y + Z = 100% of the total tumour area. ( E ) The 5-tier score for nuclear NEDD8 (NEDD8n) according to the percentage of positive cells.

Article Snippet: The AGTRAP, ALKBH3 and DIVERSIN antibodies were purchased from Proteintech Europe (Manchester, UK), while NEDD8 and RRM1 were from Cell Signaling Technology (Frankfurt am Main, Germany).

Techniques: Marker, Expressing